Loading...
XSHG
600201
Market cap2.11bUSD
Dec 05, Last price  
13.40CNY
1D
3.08%
1Q
64.01%
Jan 2017
-22.81%
Name

Jinyu Bio-Technology Co Ltd

Chart & Performance

D1W1MN
XSHG:600201 chart
P/E
136.69
P/S
11.87
EPS
0.10
Div Yield, %
0.60%
Shrs. gr., 5y
-0.11%
Rev. gr., 5y
2.19%
Revenues
1.26b
-21.45%
552,597,984561,866,923702,180,147815,014,679685,494,694670,330,720576,140,310556,475,105671,382,9781,062,932,0251,246,505,8441,517,019,2831,901,010,2641,896,608,6301,126,782,2531,581,905,6321,776,317,8111,528,669,2561,598,225,4601,255,455,757
Net income
109m
-61.57%
12,281,76937,458,18792,925,47172,207,19966,473,720115,188,976149,438,394130,434,791250,883,061404,321,363479,727,738644,541,675870,094,412754,465,552221,041,634406,195,463382,286,663210,659,922283,630,790108,985,186
CFO
290m
-30.20%
28,290,477102,662,785136,094,806223,910,89800185,203,233102,946,417649,339,640585,186,590494,320,157756,123,716891,439,596422,460,842405,242,914699,612,782533,084,549344,650,092414,833,263289,552,214
Dividend
Jul 15, 20240.08 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Jinyu Bio-technology Co., Ltd. engages in the research and development, production, and sales of veterinary biological products in China. It offers vaccines for foot-and-mouth disease, highly pathogenic avian influenza, brucellosis, rabies, and swine fever for pigs, poultry, ruminants, and pets. The company was formerly known as Inner Mongolia Jinyu Group Co., Ltd. and changed its name to Jinyu Bio-technology Co., Ltd. in December 2015. Jinyu Bio-technology Co., Ltd. was founded in 1992 and is based in Hohhot, China.
IPO date
Jan 15, 1999
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT